Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482665 | 0.91 | KDM4E (0.47) | TBXA2RDRD2KDM4EPTGESCNR1 | |
| SCHEMBL1483090 | 0.90 | TBXA2R (0.46) | TBXA2RDRD2KDM4EKMT2ANR1H4 | |
| SCHEMBL1482836 | 0.89 | CCR2 (0.41) | TBXA2RDRD2KDM4EPTGESCNR1 | |
| SCHEMBL1482646 | 0.89 | DRD2 (0.53) | TBXA2RDRD2P2RX3KMT2ANR1H4 | |
| SCHEMBL1482644 | 0.87 | NR1H4 (0.43) | TBXA2RDRD2CNR1P2RX3NR1H4 | |
| SCHEMBL1482685 | 0.85 | KMT2A (0.48) | KDM4EPTGESKMT2ALMNA | |
| SCHEMBL1483030 | 0.84 | DRD2 (0.47) | TBXA2RDRD2CCR2P2RX3 | |
| SCHEMBL1482892 | 0.83 | KMT2A (0.45) | KDM4ECCR2KMT2AGRIN1GRIN2B | |
| SCHEMBL1484222 | 0.83 | DRD2 (0.38) | TBXA2RDRD2KMT2AMDM2GRIN1 | |
| SCHEMBL1482332 | 0.82 | DYRK1A (0.39) | KDM4ECNR1P2RX3NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | TBXA2R 92/4885DRD2 1464/4885KDM4E 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.